Dicot Pharma presents at Biostock Global Forum May 21

Uppsala, Sweden, May 19, 2026. Dicot Pharma AB will be presenting at Biostock Global Forum in Lund, May 21, 2026, at the Insights Stage. The presentation will be recorded and available for viewing afterwards, including on Dicot Pharma's website.

Dicot Pharma’s CEO Elin Trampe will present the company and its drug candidate LIB-01, which is being developed as a unique and long-acting treatment for erectile dysfunction. The Forum gathers specialized investors, experts from various aspects of the life science field, and Business Development & Licensing reps.

Dicot Pharma plans to conduct a clinical phase 2b study with LIB-01 in Europe and the US. To strengthen the company's financial position and finance the clinical phase 2b study, Dicot Pharma is conducting a rights issue between May 21 and June 4, 2026. The rights issue is secured at 80 percent, corresponding to SEK 168 million, which provides Dicot Pharma with sufficient funds to finance the study. If fully subscribed, the issue could bring the company SEK 210 million before costs.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.